

PRESCRIBING INFORMATION

^NTUSSIONEX® SUSPENSION and TABLETS (Controlled-Release Hydrocodone Resin Complex and Phenyltoloxamine Resin Complex)

Antitussive - Antihistamine

sanofi-aventis Canada Inc.
2150 St. Elzear Blvd. West
Laval, Quebec H7L 4A8

Date of Revision:
March 23, 2006

Submission Control No. 104725

s-a Version 1.2 dated July 14, 2008

PRESCRIBING INFORMATION

^NTUSSIONEX® SUSPENSION AND TABLETS

**(Controlled-Release Hydrocodone Resin Complex
and Phenyltoloxamine Resin Complex)**

Antitussive - Antihistamine

ACTION

Hydrocodone is a semi-synthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. As an antitussive, hydrocodone is approximately three times as potent as codeine on a weight for weight basis. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to inhibit coughing by interfering with the central modulation of afferent signals, thereby decreasing sensitivity of the cough centre to incoming stimuli.¹ In excessive doses, hydrocodone, like other opium derivatives, will depress respiration. Hydrocodone can produce miosis, euphoria, physical and psychological dependence.

Phenyltoloxamine, acts as competitive inhibitor of histamine². As with other antihistamines, it is possible that its sedative and tranquillizing characteristics may contribute to its antitussive action.³ In addition, phenyltoloxamine in a similar manner to other antihistamines has been shown to potentiate the effects of hydrocodone.⁴

Both of the above active ingredients are complexed to an inert cation exchange resin. It has been shown that the resin itself does not impart any additional toxicity into the final product, and the drug-resin complex produces a higher LD₅₀ in mice and rats for the drug substances than when they are administered in their free or common salt form.⁵ The time required to cause death in rats following a certain lethal dose of drug as an ion-exchange resin complex was longer than when the drug was administered as a soluble salt. These two factors combine to make these resin complexes less toxic and, hence, safer to administer orally than the soluble salt form of the drug.

The benefits derived from the sustained release action resulting from this complexing and the apparent potentiation of the narcotic antitussive effect by phenyltoloxamine constitute the basis of action of this preparation.

INDICATIONS AND CLINICAL USE

Tussionex is indicated for the treatment of exhausting or non-productive cough; associated with cold or with upper respiratory allergic condition that does not respond to non-narcotic antitussives. It is an effective antitussive which acts for approximately 8 to 12 hours.

CONTRAINDICATIONS

Hypersensitivity to any of the components, marked hypertension, patients receiving monoamine oxidase (MAO) inhibitors, pre-existing respiratory depression, intracranial lesions with increased intracranial pressure.

WARNINGS

It is important to provide appropriate therapy for the primary disease and to ensure that modification of the cough does not increase the risk of physical or psychological complications.

Children: in young children, the respiratory centre is especially susceptible to the depressant action of narcotic cough suppressants.

Pregnancy and Lactation: Since hydrocodone crosses the placenta, its use in pregnancy is not recommended. Babies of nursing mothers using opioids may become physically dependent.

Hydrocodone may inhibit peristalsis, and patients with chronic constipation should be given Tussionex only after weighing the potential therapeutic benefit against the hazards involved.

Occupational hazards: Caution patients not to operate vehicles or hazardous machinery until their response to the drug has been determined.

Since the depressant effects of some antihistamines are additive to those of other drugs affecting the CNS, caution patients against drinking alcoholic beverages or taking hypnotics/sedatives, tricyclic antidepressants, benzodiazepines or other opiate agonists during antihistaminic therapy.

Tussionex contains hydrocodone: may be habit forming.

Tussionex suspension must not be diluted with fluids or mixed with other drugs because this alters the resin-binding and changes the absorption rate, possibly increasing the toxicity.

PRECAUTIONS

Before prescribing medication to suppress or modify cough, it is important to identify the underlying cause of the cough.

In young children, the benefit to risk ratio should be carefully considered, especially in children with respiratory embarrassment (e.g. croup).

Use with caution in patients with hypertension, diabetes mellitus, thyrotoxicosis, glaucoma, cardiac disease and peripheral vascular disease and in patients receiving methyldopa or beta adrenergic blockers.

The use of hydrocodone bitartrate over a prolonged period may, in susceptible individuals, lead to habituation and, in some cases, true addiction.

ADVERSE REACTIONS

Negligible, but when encountered may include mild constipation, nausea, facial pruritus, and drowsiness that disappear with adjustment of dose or discontinuance of treatment.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Symptoms: are similar to those of codeine overdose. Narcosis is usually present, sometimes associated with convulsions. Tachycardia, bradycardia, pupillary constriction, nausea and vomiting and respiratory depression can occur. The resinated formulation mitigates the immediate absorption of large quantities of hydrocodone; however, the absorption period may be prolonged.

Treatment: If respiration is severely depressed, administer the narcotic antagonist, naloxone. Adults: 0.4 mg to 2.0 mg by intravenous, intramuscular or subcutaneous routes and repeated at 2 to 3 minute intervals if necessary. Children: 0.01 mg/kg by intravenous, intramuscular or subcutaneous routes. Dosage may be repeated also at 2 to 3 minute intervals if necessary. Since the duration of action of hydrocodone in this formulation may exceed that of naloxone, the patient should be kept under surveillance and repeated doses of naloxone should be administered as needed. Failure to obtain significant improvement after 2 to 3 doses suggests that causes other than narcotic overdose may be responsible for the patient's condition.

If naloxone is unsuccessful, institute intubation and respiratory support and conduct gastric lavage in the unconscious patient.

Convulsions, sometimes seen in children, can be controlled by intravenous administration of benzodiazepines (e.g., diazepam).

DOSAGE AND ADMINISTRATION

Tussionex should not be diluted with fluids or mixed with other drugs. Shake well before using.

Dosage in Adults: 5mL (1 teaspoonful) of suspension or one tablet every 8 to 12 hours. Maximum daily dose is 10mL of suspension or 2 tablets. May be adjusted to individual requirements.

Dosage in Children (Suspension): From 1 to 5 years: 2.5mL (1/2 teaspoonful) every 12 hours (maximum daily dose of 5mL or 1 teaspoonful). Over 5 years: 5mL (1 teaspoonful) every 12 hours (maximum daily dose of 10mL or 2 teaspoonsful). Tussionex is not recommended for children under the age of 1 year or weighing less than 9 kg.


PHARMACEUTICAL INFORMATION

DRUG SUBSTANCE

1. Proper Name: Hydrocodone Bitartrate

Chemical Name: 4,5 α Epoxy - 3 methoxy -17- methylmorphinan -6- one tartrate.

Structural Formula:




Molecular Weight: 494.5

Description: a white crystalline powder, soluble in water, melting point of 186° to 190°C.

2. Proper Name: Phenyltoloxamine Citrate

Chemical Name: N,N - Dimethyl -2- (α - phenyl -0- tolyloxy) ethylamine.

Structural Formula:



Molecular Weight: 255.4

Description: a white crystalline powder, soluble in water, pH of 1% solution in water is 3.2 to 4.2, melting point 138 to 140°C.

3. Proper name: Polystyrene Resin

NON-MEDICINAL INGREDIENTS

Liquid: sorbital, ethanol, propylene glycol, glycerin, xanthan gum, water, pineapple flavour, peach flavour, methylparaben, propylparaben, FD&C yellow No. 10, FD&C yellow No. 6.

Tablets: starch, sugar, lactose monohydrate, water, calcium phosphate dibasic, colloidal silicon dioxide, magnesium stearate.

STABILITY AND STORAGE CONDITIONS

Liquid and Tablet: Store at room temperature.

DOSAGE FORMS

Availability

Each light brown, scored tablet or each 5 mL of neutral tasting, gold-coloured, thixotropic suspension contains: hydrocodone resin complex equivalent to 5 mg of hydrocodone bitartrate and phenyltoloxamine resin complex equivalent to 10mg of phenyltoloxamine citrate. The suspension is available in bottles of 500 mL. The tablets are available in bottles of 100.

CLINICAL PHARMACOLOGY

In a study of 44 pulmonary tuberculosis patients, hydrocodone was found to be highly effective as a cough suppressant in diminishing the intensity and frequency of the cough. However, when the tracheobronchial secretions reach the irritable level, patients had no difficulty expelling sputum.⁶

Cass and Frederik studied the long-term (from 3 to 29 months) effectiveness of Tussionex in the control of chronic cough due to asthma, bronchitis, tuberculosis, and emphysema⁷. Cough was suppressed without an increase in sputum. Tussionex retained its effectiveness over the course of the study. The antitussive medication was limited to two doses daily. In only one instance was it necessary to stop the medicine because of drowsiness. There was no evidence of addiction.

Tussionex has been found to provide excellent antitussive results lasting from eight to twelve hours^{3,4,8}. Townsend carried out a clinical study on 356 patients with cough associated with measles, upper respiratory infection, and bronchitis, and with so-called allergic cough, and nocturnal cough with emesis. One group of patients received an aqueous solution of hydrocodone 5 mg/mL plus phenyltoloxamine 10 mg/5 mL. The second group received a resinated complex of the same drugs in equivalent dosage concentrations. Eighty-four percent of the patients receiving the resinated formulation experienced cough suppression for 10 hours or more. For those receiving the aqueous solution, a 4-hour cough suppression was maximal and was attained in only 36% of these patients.³

It has been found that antihistamines may potentiate the antitussive effects of hydrocodone. In a laboratory study using mongrel dogs, Chan and Hays compared the relative cough-suppressant effectiveness of (a) codeine (2.2 mg/kg), (b) hydrocodone (3.7 mg/kg), (c) hydrocodone (0.37 mg/kg) as a resin complex, and (d) hydrocodone (0.37 mg/kg) plus phenyltoloxamine (2.2 mg/kg) both as resin complexes.⁴

The antitussive effects of both the codeine and hydrocodone solutions disappeared after 5 and 6 hours respectively. By 10 hours into the experiment, the resinated hydrocodone formulation had also lost its effect, but the hydrocodone/phenyltoloxamine resin complex was still providing cough suppression even after 13 hours.

In a subsequent clinical study, these investigators noted that while Tussionex effectively suppressed the hacking non-productive cough for 8 to 12 hours, the less frequent productive cough still appeared and performed its physiological role.⁴

In another double-blind clinical study, Cass compared the relative clinical effectiveness of four antitussive preparations.

Each dose of the four preparations contained the following:

	mg/dose
1. Hydrocodone (as an ion exchange resin)	1.66
Phenyltoloxamine	5
Chlorpheniramine	3
Ephedrine	25
Guaiacol Carbonate	20
2. Hydrocodone	5
Homatropine methylbromide	1.5
Pyrilamine maleate	12.5
Ammonium chloride	60
Phenylephrine hydrochloride	10
Sodium citrate	85
3. Hydrocodone (as an ion exchange resin)	5
Phenyltoloxamine (as an ion exchange resin)	10
4. Codeine (as an ion exchange resin)	10
Phenyltoloxamine (as a controlled-release resin)	5
Chlorpheniramine (as a controlled-release resin)	3
Ephedrine (as a controlled-release resin)	25
Guaiacol Carbonate	20

The hydrocodone/phenyltoloxamine resin complex provided consistently superior results, compared to the other preparations, measured as the percent of maximal cough suppression achieved.⁹

Cass and Frederik (1958) in one double-blind study and one single blind study involving 127 chronic cough patients verified the 12-hour duration of cough relief provided by the Tussionex formulation. Control of cough was again 2 to 3 times longer than for the same active ingredients in aqueous salt form.⁸

BIBLIOGRAPHY

1. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. Goodman and Gilman's Pharmacological basis of therapeutics. Toronto: Collier Macmillan Canada 1985:491-531.
2. Hoekstra JB, Tisch DE, Rakieten N, Dickison HL. Pharmacological properties of a new antihistaminic agent, phenyltoloxamine (Bristamin). Journal of the American Pharmaceutical Association 1953; 42:587-593.
3. Townsend EH. Prolonged cough suppression. New England Journal of Medicine 1958; 258:63-67.
4. Chan YT, Hays EE. A resin complex for prolonged antitussive effects. The American Journal of the Medical Sciences 1957; 234:207-212.
5. Becker BA, Swift JG. Effective reduction of the acute toxicity of certain pharmacological agents by use of synthetic ion exchange resins. Toxicology and Applied Pharmacology 1959; 1:42-54.
6. Hyman S, Rosenblum SH. Clinical evaluation of a new antitussive agent. Illinois Medical Journal 1953; 104:257-259.
7. Cass LJ, Frederik WS. The prolonged use of a sustained release antitussive. Report dated 11/25/59 on file with University Health Services, Harvard University, Cambridge, Massachusetts, USA.
8. Cass LJ, Frederik WS. The clinical evaluation of sustained released antitussives. Annals of Internal Medicine 1958; 49:151-160.
9. Cass LJ. The clinical evaluation of a new sustained-release antitussive of low narcotic content. Current Therapeutic Research 1961; 3:355-359.